SOUTHPORT, N.C., Nov. 07, 2022 (WORLD NEWSWIRE)– Cygnus Technologies, part of Maravai LifeSciences (Maravai) (NASDAQ: MRVI), the leading assay and companies for the detection and characterization of process-related pollutants in biopharmaceuticals, revealed today the launch of the MockV ® RVLP Package. This package allows bioprocess researchers to measure the elimination of Retrovirus-Like Particles (RVLPs) produced endogenously by Chinese Hamster Ovary (CHO) cell lines throughout biopharmaceutical production. The package consists of an extremely cleansed and focused stock option of RVLPs in addition to the needed reagents for precise and reputable RVLP metrology.
Viral contamination is a fundamental danger throughout the manufacture of biopharmaceutical items such as antibodies, gene treatments, vaccines, and plasma derivatives. Whether presented at first from basic materials or later on through particular making operations, straight-out viral contamination has actually caused major health ramifications and plant shutdowns. International regulative firms need sponsoring business to verify the viral clearance effectiveness of their filtration procedure actions prior to medical trials or regulative approval.
Cygnus’s MockV ® innovation resolves the barriers enforced by live viral clearance research studies through the unique and patent-protected usage of viral surrogates, or “Mock Viral Particles (MVPs)”. MVPs are crafted to simulate the physical and chemical attributes of infections however are themselves non-infectious. They can for that reason be dealt with securely and quickly to forecast the results of CRO-led spiking research studies early in procedure advancement. In this method, Cygnus’s MockV ® innovation can play a crucial function in assisting biopharmaceutical business establish making procedures that successfully get rid of viral contamination, causing the production of safe biotherapeutics.
Cygnus’s MockV ® RVLP Package is the 2nd line of product in the MockV ® portfolio and the very first presented because the acquisition of MockV Solutions by Maravai in 2020. The stock option of RVLP offered by this package includes a real non-infectious retrovirus-like impurity created throughout CHO production. In the early 1990s, worldwide regulative firms such as the FDA recognized the occurrence of this particle and ended up being worried about the retroviral security of CHO-derived biopharmaceuticals. Ever since, the biopharmaceutical market has actually depended on CROs to propagate Xenotropic Murine Leukemia Infection (XMuLV) as a design retrovirus to show reliable clearance. With the schedule of the MockV ® RVLP Package, biopharmaceutical business can now individually examine the elimination of the initial retroviral particle of regulative issue, obtained straight from CHO cells.
Christine Dolan, Cygnus Technologies Chief Operating Officer, commented, “We are significantly delighted to release this extremely prepared for viral clearance package within our MockV ® line of product. This launch is the conclusion of considerable development and thoughtful application by the line of product innovator, David Cetlin and his group.” Cetlin included, “The RVLP Package addresses an unmet requirement for the market to carry out these research studies in their own laboratory and on their timeline. Our vision is that the information our consumers will produce through using this package will affect their procedure advancement and optimization choices, eventually leading them to more reliable viral clearance procedure actions.”
About Cygnus Technologies, LLC
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical market’s partner in host cell protein (HCP) and other process-related pollutant detection and analytics along with in ingenious viral clearance options. Cygnus assists business establishing restorative proteins, vaccines, antibodies, plasma derivatives and gene treatments to guarantee the security of biotherapeutics prior to human trials, regulative approval and industrial release. For more details on Cygnus Technologies, please go to www.cygnustechnologies.com
About Maravai
Maravai is a leading life sciences business offering vital items to make it possible for the advancement of drug treatments, diagnostics and unique vaccines. Maravai’s business are leaders in offering product or services in the fields of nucleic acid synthesis and biologics security screening to much of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene treatment business.
For more details about Maravai LifeSciences, visit www.maravai.com.
